Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Sales Stall in Q4 After Tools Business Divestiture

NEW YORK (GenomeWeb News) — Ciphergen’s fourth-quarter revenues plunged 440 percent as R&D spending fell 9 percent and losses decreased 80 percent, the company said today.
 
Total receipts for the three months ended Dec. 31 decreased to $1.2 million from $6.6 million year over year.
 
Ciphergen said its only revenue in the fourth quarter came from the sale of instruments and tools before it sold its life sciences business to Bio-Rad Laboratories last November.   
 
R&D spending decreased to $2.7 million from $3 million year over year.
 
The company said losses declined to $1.9 million from $9.2 million in the year-ago period.
 
Ciphergen said it had around $17.7 million in cash and cash equivalents as of Dec. 31.
 
Since the sale of its life sciences business, the company is “focused on leveraging our proteomics and biomarkers to build a leading diagnostics company,” CEO Gail Page said in a statement.
 
Page said the company has three tests, including an ovarian triage test, in validation and clinical studies, and other potential diagnostics.
 
Ciphergen said it does not expect to see any revenue until those diagnostics become marketed.
 
The company, which has a staff of 40 after the Bio-Rad deal, said it expects expenses to be “substantially reduced” in 2007 and said it plans to use about $5 million of its cash reserves in the first quarter.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.